



XOMA Corporation
Investor Relations Department
2910 Seventh St.
Berkeley, CA 94710
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: XOMA ¹

| | |
|-------------------|----------------------------|
| Last Trade: | 7.27 |
| Trade Time: | 3:59 PM ET Jul 21, 2017 |
| Change: | -0.14 (1.889%) |
| Day Range | 7.25 - 7.56 |
| 52-Week Range | 3.96 - 13.98 |
| Volume | 40,424 |
| Market Cap. (\$M) | 55.179 |
| Shares Out (M) | 7.590 |

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

XOMA Corporation (Nasdaq: XOMA) is a biotechnology company focused on the discovery, development and manufacturing of monoclonal antibody-based therapeutics for serious unmet medical needs. XOMA's world-class monoclonal antibody technologies have contributed to the development of marketed biologics with a total of more than \$1 billion in annual sales and for which XOMA received substantial royalties. The company also has a strong track record of product discovery and development collaborations with pharmaceutical and biotechnology companies and the U.S. government, and has licensed certain of its fundamental technologies to more than 60 companies.... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 18, 2017 [XOMA Earns \\$10 Million Milestone Payment as Another of its Licensed Assets Advances into Clinical Development](#)
- May 15, 2017 [XOMA to Present New Strategic Initiatives at the UBS Global Healthcare Conference](#)
- May 9, 2017 [XOMA Reports First Quarter 2017 Financial Results](#)
- Apr 24, 2017 [XOMA Announces Positive Results from its Phase 2 Proof-Of-Concept Study of Prolactin Inhibition](#)
- Apr 18, 2017 [XOMA Presents Positive Data from PTH1R Monoclonal Antibody Program](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

- Mar 16, 2017 [Annual Report \(10-K\)](#)
- Apr 5, 2017 [Definitive Proxy Statement](#)
- May 9, 2017 [Quarterly Report \(10-Q\)](#)
- Nov 9, 2016 [Quarterly Report \(10-Q\)](#)
- Aug 3, 2016 [Quarterly Report \(10-Q\)](#)